Quantcast

Industry news that matters to you.  Learn more

Novel Use of Pressure BioSciences’ Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design

Last month, Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) announced that data supporting important advantages of PBI’s powerful and enabling Pressure Cycling Technology (“PCT”) platform were presented at the 27th Annual Symposium of the Protein Society held July 20-23, 2013 in Boston, Massachusetts.

The use of highly sophisticated analytical instrument systems by research scientists worldwide has resulted in a greater understanding of complex biological molecules, including proteins – the “building blocks of life.” One such instrument system, Electron Paramagnetic Resonance (“EPR”) spectroscopy, has been shown to provide key information on the structure, flexibility, and function of proteins. This information is crucial to the development of new and better diagnostics, therapeutics, and vaccines.

At this year’s annual Protein Society symposium, researchers from UCLA reported on the development of an improved EPR system based on the use of high pressure. This novel system combined (for the first time ever) two cutting-edge EPR methods: site directed spin labeling (“SDSL”) and double electron-electron resonance (“DEER”). This strategy allowed the investigation of dynamic events in proteins that would be difficult or even impossible to study by conventional EPR technology.

Dr. Wayne L. Hubbell, Distinguished Professor of Chemistry and Biochemistry and Jules Stein Professor of Ophthalmology at UCLA, and senior author of the study, commented: “The study of proteins under pressure by EPR and other spectroscopic techniques, such as Nuclear Magnetic Resonance (“NMR”), has the potential to greatly improve our understanding of the structure and function of proteins. This information could subsequently provide new insights into such important areas as biomarker discovery and rational drug design, and play an important role in the discovery process that lies ahead in the exciting field of protein science.”

Richard T. Schumacher, President and CEO of PBI, said: “We believe these and other data reported by researchers using pressure-based EPR and NMR systems strongly indicate that PCT can enhance the recovery, detection, and measurement of proteins from a wide variety of samples. In turn, this information has the potential to help accelerate the design and manufacture of new and better diagnostics, therapeutics, and vaccines. We further believe that the advantages of pressure-based spectroscopic methods are just now beginning to be realized by scientists, and that as the body of data continues to grow from high pressure-based spectroscopic studies, that PBI has the potential to become a major provider of high pressure equipment into the exciting and growing spectroscopy area.”

Source: Pressure BioSciences

Agilent Technologies and SomaLogic Enter Agreement to Expand Access to Cutting-Edge Proteomic Technology

Agilent Technologies Inc. (NYSE: A) and SomaLogic Inc. (a privately held biotechnology company) recently announced that they have entered into an agreement to expand access to SomaLogic’s unbiased protein biomarker discovery platform.

The companies will initially place SomaLogic’s SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. Although the SOMAscan assay is already available to researchers directly from SomaLogic as a service, this planned roll-out is aimed at meeting the rapidly growing demand for access to SomaLogic’s highly multiplexed, cost-effective proteomic analyses.

“This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market,” said Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division. “SomaLogic’s cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market.”

“Agilent’s custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years,” said Larry Gold, Ph.D., chairman and CEO of SomaLogic. “We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere.”

Terms of the agreement were not disclosed.

Source: Business Wire

Genewiz, Inc. Announces Collaboration with BeiGene, Ltd.

GENEWIZ, Inc., leading global genomics service provider, recently announced a collaboration with BeiGene, a biotechnology company focused on the discovery and development of innovative oncology treatment. The two companies will work together to accelerate cancer biomarker discovery, which will later aid drug target identification.

Headquartered in Beijing, BeiGene has established more than one hundred patient-derived primary tumor models in-house as part of their portfolio of oncology target therapies in early stage development. Utilizing OncoGxOne™ Discovery cancer panels, BeiGene will have the ability to identify and understand genetic variations in prevalent cancers throughout China and the Asia-Pacific region.

“Our collaboration with GENEWIZ and application of the OncoGxOne™ cancer panels will enable characterization of primary tumor models at the genetic level, with a focus on aberrations in cancer related genes,” stated Dr. Lai Wang, Head of Discovery Biomarkers, BeiGene.

“Due to the unique ability to detect aberrations including gene fusions and copy number variance (CNV), using OncoGxOne™ Discovery cancer panels we have capabilities to identify novel mutations present in BeiGene’s primary cancer tumor models,” commented Dr. Guanghui Hu, Vice President of Translational Genomics. “Later, this invaluable information can be used for cancer diagnosis and treatment, which will have a direct impact on patient treatment and quality of life.”

“We believe that this collaboration will strongly support our translational research and biomarker discovery,” asserted Dr. Wang.

Source: Genewiz

Genewiz, Inc. and the John Theurer Cancer Center at Hackensack University Medical Center Announce Collaboration to Advance Ovarian Cancer Biomarker Discovery

GENEWIZ, Inc., leading global genomics service provider, and the John Theurer Cancer Center at Hackensack University Medical Center recently announced a collaboration that will combine efforts towards the advancement of ovarian cancer biomarker discovery research.

This research collaboration will enable analysis of ovarian cancer samples for the identification of biomarkers predicting prognosis and chemotherapy outcomes for ovarian cancer. GENEWIZ will process and analyze clinical samples supplied by the John Theurer Cancer Center in CLIA-certified, CAP-accredited laboratories located at their global headquarters in South Plainfield, NJ.

“GENEWIZ’s cutting-edge genomic analysis technologies and informatics capabilities, including our recently launched OncoGxOne™ Discovery ovarian cancer panel, enable us to comprehensively assay ovarian cancer-related genes for the detection of all types of genomic aberrations, including gene fusions and copy number variance (CNV), in addition to Indels and point mutations,” stated Dr. Shihong Li, GENEWIZ Principal Investigator.

“Working with GENEWIZ offers the confidence of proven competencies in comprehensive genomic analysis for cancer research, as well as the benefit of having a CLIA-certified, CAP-accredited laboratory for working with our clinical samples,” remarked Dr. K. Stephen Suh, Principal Investigator at the John Theurer Cancer Center at Hackensack University Medical Center. “We are excited to work together for the improvement of cancer care and women’s health overall.”

Source: Genewiz

Metabolon Announces Findings From Two Major Diabetes Outcomes Studies For its Quantose Prediabetes Test

Metabolon, Inc. a pioneering leader of advanced metabolomics, announced outcome results recently from two large-cohort studies evaluating the clinical utility of Quantose, the company’s blood test for prediabetes. The studies provided further evidence that the Quantose test identifies individuals at risk for type 2 diabetes earlier and more accurately than traditional risk factors alone.

The performance of Quantose was measured among 3,841 participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) and Botnia Prospective Study cohorts. Notably, among initially healthy participants in the RISC study with 3-year follow-up data:

  • Quantose biomarkers α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) independently and significantly predicted worsening glycemic control, and;
  • Quantose outperformed traditional risk measures such as fasting insulin, fasting glucose, BMI, and HOMA-IR in predicting insulin resistance and progression to impaired glucose tolerance.

In the Botnia Prospective Study with 9.5 year follow-up data:

  • Quantose biomarkers were found to predict incident type 2 diabetes independent of familial diabetes, sex, age, BMI, and fasting glucose.

These findings were published in two recent articles:

“Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance”, Diabetes; Ferrannini, Gall, et.al.; 2013; 62(5): 1730.

“A Novel Fasting Blood Test for Insulin Resistance and Prediabetes” Journal of Diabetes Science and Technology; Ferrannini, Cobb, et.al.; 2013; 7(1): 100.

The Quantose test reflects insulin resistance and detects progression to prediabetes and diabetes earlier than traditional glycemic measures such a hemoglobin A1C. The test is particularly useful in identifying prediabetic patients at greatest risk of disease progression and for whom drug, or other interventional therapy, may be appropriate. Diagnostic assessment with the Quantose test is well-aligned with the American Diabetes Association guidelines which recommend that physicians consider pharmaceutical intervention in high-risk prediabetics.

Beyond its immediate impact on the treatment of prediabetes, Quantose offers convincing evidence of the maturation of the field of metabolomics — and of the potential influence the discovery of novel metabolomic biomarkers will have on personalized medicine. Metabolon is committed to utilizing its systematic metabolomics discovery approach to develop diagnostics in the areas of metabolic, cancer and cardiovascular disease and provide biomarker research services by employing their high-throughput, advanced metabolomics platform.

“These studies are clear affirmation of Quantose value to predict early those individuals at risk for eventual onset of Type 2 diabetes which may provide clinicians the opportunity for treatment interventions that may reverse the prediabetic state.”, Eric Button, Senior Vice President of Diagnostics, Metabolon commented. Eric and other biomarker discovery experts from Metabolon will be present on July 22-24th at the 73rd Scientific Sessions of the American Diabetes Association. Visit booth #776 for more information regarding these studies or schedule an appointment with an expert to learn more about the Quantose test.

Study: Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance

Study: A Novel Fasting Blood Test for Insulin Resistance and Prediabetes

Source: Metabolon